Načítá se...
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
SIMPLE SUMMARY: The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rates. These agents are actively being investigated earlier in the sequence of therapi...
Uloženo v:
| Vydáno v: | Cancers (Basel) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7601361/ https://ncbi.nlm.nih.gov/pubmed/33050054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102887 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|